既往中重度血小板减少的转移性去势抵抗性前列腺癌患者接受PSMA放射性配体治疗的安全性
本研究纳入17例既往血小板减少(血小板计数<75×10⁹/L)的转移性去势抵抗性前列腺癌患者,接受中位3周期[177Lu]Lu-PSMA-617治疗。各周期及治疗前后血小板计数均无显著差异,未见因血小板减少导致的严重出血事件,提示PSMA放射性配体治疗在此类患者中可行。
要点
- 17例既往血小板减少的mCRPC患者接受中位3周期[177Lu]Lu-PSMA-617治疗。
- 各周期及治疗前后血小板计数均无显著差异,未见严重出血事件。
- 作者认为血小板减少患者不应被绝对排除在PSMA放射性配体治疗之外。
核心结论
- 尽管既往明显血小板减少常被视为放射性配体治疗的禁忌证,本研究表明既往≥2级血小板减少患者接受PSMA放射性配体治疗可行,未观察到治疗导致的血小板计数显著恶化。
- 作者认为血小板减少患者不应被绝对排除在PSMA放射性配体治疗之外。
研究设计与样本
- 本研究纳入17例既往血小板减少(血小板计数<75×10⁹/L)的转移性去势抵抗性前列腺癌患者。
- 患者接受中位3周期(范围1-6)[177Lu]Lu-PSMA-617治疗,密切监测血小板计数并按CTCAE分析。
主要发现
- 第一周期基线血小板54.18±16.07 vs 随访59.65±39.16(×10⁹/L),p=0.834。
- 第二周期基线58.56±16.43 vs 随访107.1±56.44(×10⁹/L),p=0.203。
- 第三周期基线60.38±16.57 vs 随访132.1±80.43(×10⁹/L),p=0.148。
- 治疗结束与基线比较(不考虑周期数)54.18±16.07 vs 72.06±71.9(×10⁹/L),p=0.741。
- 治疗结束后CTCAE评分稳定者占29.4%,升高者占41.2%,改善者占29.4%;未见因血小板减少导致的严重出血事件。
临床怎么用
- 作者认为,既往≥2级血小板减少患者接受PSMA放射性配体治疗可行,不应被绝对排除在治疗之外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting moderate to severe thrombocytopenia (CTCAE ≥ 2). MATERIALS AND METHODS: Seventeen mCRPC patients with preexisting thrombocytopenia (platelet count < 75 × 109/L) were included in this study. Patients received a median of 3 cycles of [177Lu]Lu-PSMA-617 (range 1-6). The course of platelet cell count was closely monitored within and after the PSMA-RLT and analyzed statistically and according to CTCAE. RESULTS: No significant difference in platelet counts was observed between baseline and follow-up after each PSMA-RLT cycle: first cycle (54.18 ± 16.07 at baseline vs. 59.65 ± 39.16 at follow up [in × 109/L], p= 0.834), second cycle (58.56 ± 16.43 vs. 107.1 ± 56.44, p = 0.203), and third cycle (60.38 ± 16.57 vs. 132.1 ± 80.43, p = 0.148), respectively. Similarly, baseline and end of treatment values, irrespective of the number of administered cycles, did not reveal a significant difference (54.18 ± 16.07 vs. 72.06 ± 71.9, p = 0.741). After the end of therapy, irrespective of the number of administered cycles, 29.4% of patients remained stable in terms of CTCAE scoring, 41.2% changed to a higher score and 29.4% improved to a lower score. We observed no critical bleeding events due to thrombocytopenia. CONCLUSION: Despite the common consideration of marked preexisting thrombocytopenia as a contraindication for RLT, this study indicates feasibility of PSMA-RLT in patients with preexisting thrombocytopenia of grade ≥ 2, as in our preliminary experience, there was no RLT-induced significant deterioration of platelet cell count. Thus, patients with thrombocytopenia should not be categorically excluded from receiving PSMA-RLT.
引用
- Bastian MB, Sieben M, Blickle A, et al. Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia. Eur J Nucl Med Mol Imaging. 2024. PMID: 39625666. doi:10.1007/s00259-024-07006-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。